Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
1. SNY has formed a Golden Cross, indicating bullish momentum. 2. The stock is up 21.89% year-to-date, showing strong gains. 3. Dupixent's Phase 2/3 trial results enhance its market potential. 4. FDA priority review for Dupixent could yield results by 2025. 5. Momentum traders are driving interest in SNY's recent performance.